Patents by Inventor Jon O. Nagy
Jon O. Nagy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11337924Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.Type: GrantFiled: June 18, 2019Date of Patent: May 24, 2022Assignees: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Tim Triche, Hyung-Gyoo Kang
-
Publication number: 20220117894Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Applicants: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Timothy J. Triche, HyungGyoo Kang
-
Publication number: 20190365650Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.Type: ApplicationFiled: June 18, 2019Publication date: December 5, 2019Applicants: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Tim Triche, Hyung-Gyoo Kang
-
Patent number: 10369104Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.Type: GrantFiled: April 1, 2015Date of Patent: August 6, 2019Assignees: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Tim Triche, Hyung-Gyoo Kang
-
Patent number: 9956176Abstract: Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.Type: GrantFiled: January 23, 2017Date of Patent: May 1, 2018Assignees: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Timothy Triche, Hyung-Gyoo Kang, Sheetal Mitra
-
Publication number: 20170143630Abstract: Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.Type: ApplicationFiled: January 23, 2017Publication date: May 25, 2017Applicants: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Timothy Triche, Hyung-Gyoo Kang, Sheetal Mitra
-
Publication number: 20170020816Abstract: The invention relates to a novel drug delivery vehicle. Various embodiments of the invention provide a hybrid polymerized liposomal nanoparticle comprising both polymerizable lipids and non-polymerizable lipids. Therapeutic agents can be loaded into the polymerized liposomal nanoparticle and targeting agents can be conjugated to the surface of the polymerized liposomal nanoparticle. Also described in the invention are methods, compositions and kits that utilize the hybrid polymerized liposomal nanoparticle to treat disease conditions such as various cancers.Type: ApplicationFiled: April 1, 2015Publication date: January 26, 2017Applicants: Children's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.Inventors: Jon O. Nagy, Tim Triche, Hyung-Gyoo Kang
-
Publication number: 20140199233Abstract: The present invention relates to the fabrication and uses of liposomal nanoparticles.Type: ApplicationFiled: May 11, 2012Publication date: July 17, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, NANOVALENT PHARMACEUTICALS, INC.Inventors: Jon O. Nagy, Noah Federman, Christopher Denny, James S. Tomlinson
-
Publication number: 20080233181Abstract: The present invention relates to nanoparticle vaccine adjuvants comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: ApplicationFiled: October 19, 2007Publication date: September 25, 2008Inventors: Jon O. Nagy, Benfang Lei, Zengshe Kevin Liu, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Patent number: 7285289Abstract: The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: GrantFiled: April 14, 2003Date of Patent: October 23, 2007Inventors: Jon O. Nagy, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Publication number: 20040022840Abstract: The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.Type: ApplicationFiled: April 14, 2003Publication date: February 5, 2004Inventors: Jon O. Nagy, Robert F. Bargatze, John W. Jutila, Jim E. Cutler, Pati M. Glee
-
Patent number: 6663886Abstract: This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.Type: GrantFiled: April 27, 2001Date of Patent: December 16, 2003Assignee: Regents of the University of CaliforniaInventors: Jon O. Nagy, Robert F. Bargatze
-
Publication number: 20030129618Abstract: The present invention relates to methods and compositions for the detection of analytes using the fluorescence that occurs in polymeric material in response to selective binding of analytes to the polymeric materials. In particular, the present invention allows for the fluorescent detection of membrane modifying reactions and analytes responsible for such modifications and for the screening of reaction inhibitors.Type: ApplicationFiled: August 9, 2002Publication date: July 10, 2003Applicant: Regents of the University of CaliforniaInventors: Mario Manuel Moronne, Deborah H. Charych, Jon O. Nagy
-
Publication number: 20010046970Abstract: This invention provides compositions for inhibiting the binding between two cells, one expressing P- or L-selectin on the surface and the other expressing the corresponding ligand. A covalently crosslinked lipid composition is prepared having saccharides and acidic group on separate lipids. The composition is then interposed between the cells so as to inhibit binding. Inhibition can be achieved at an effective oligosaccharide concentration as low as 106 fold below that of the free saccharide. Since selectins are involved in recruiting cells to sites of injury, these composition scan be used to palliate certain inflammatory and immunological conditions.Type: ApplicationFiled: June 22, 2001Publication date: November 29, 2001Inventors: Jon O. Nagy, Wayne R. Spevak, Falguni Dasgupta, Carolyn Bertozzi
-
Publication number: 20010036931Abstract: This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.Type: ApplicationFiled: April 27, 2001Publication date: November 1, 2001Inventors: Jon O. Nagy, Robert F. Bargatze
-
Patent number: 6299897Abstract: This invention provides compositions for inhibiting the binding between two cells, one expressing P- or L-selectin on the surface and the other expressing the corresponding ligand. A covalently crosslinked lipid composition is prepared having saccharides and acidic group on separate lipids. The composition is then interposed between the cells so as to inhibit binding. Inhibition can be achieved at an effective oligosaccharide concentration as low as 106 fold below that of the free saccharide. Since selectins are involved in recruiting cells to sites of injury, these composition scan be used to palliate certain inflammatory and immunological conditions.Type: GrantFiled: November 15, 1999Date of Patent: October 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Wayne R. Spevak, Falguni Dasgupta, Caroline Bertozzi
-
Patent number: 6235309Abstract: This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.Type: GrantFiled: February 27, 1998Date of Patent: May 22, 2001Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Robert F. Bargatze
-
Patent number: 5985852Abstract: This invention provides compositions for inhibiting the binding between two cells, one expressing P- or L-selectin on the surface and the other expressing the corresponding ligand. A covalently crosslinked lipid composition is prepared having saccharides and acidic group on separate lipids. The composition is then interposed between the cells so as to inhibit binding. Inhibition can be achieved at an effective oligosaccharide concentration as low as 10.sup.6 fold below that of the free saccharide. Since selectins are involved in recruiting cells to sites of injury, these composition scan be used to palliate certain inflammatory and immunological conditions.Type: GrantFiled: February 16, 1999Date of Patent: November 16, 1999Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Wayne R. Spevak, Falguni Dasgupta, Caroline Bertozzi
-
Patent number: 5962422Abstract: This invention provides a system for inhibiting the binding between two cells, one expressing P- or L-selectin on the surface and the other expressing the corresponding ligand. A covalently crosslinked lipid composition is prepared having saccharides and acidic group on separate lipids. The composition is then interposed between the cells so as to inhibit binding. Inhibition can be achieved at an effective oligosaccharide concentration as low as 10.sup.6 fold below that of the free saccharide. Since selectins are involved in recruiting cells to sites of injury, this system can be used to palliate certain inflammatory and immunological conditions.Type: GrantFiled: February 28, 1997Date of Patent: October 5, 1999Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Wayne R. Spevak, Falguni Dasgupta, Carolyn Bertozzi
-
Patent number: 5212075Abstract: Compositions and methods for the inhibition and prevention of pathogenic infection and neoplastic disease are provided. The compositions include hybrid molecules having a binding moiety and an effector moiety joined by a linker region. When administered to a host, the binding moiety, such as a carbohydrate, attaches to a receptor, such as a conserved lectin receptor on the pathogen or neoplastic cell, and the effector moiety provides an invariant antigenic determinant for eliciting or modulating an immune response. The effector moiety may also be a drug or other compound which inhibits growth of a bound pathogen or cell. Compositions comprising the hybrid molecule in a suitable pharmaceutical carrier are also provided.Type: GrantFiled: April 15, 1991Date of Patent: May 18, 1993Assignee: The Regents of the University of CaliforniaInventors: Mark D. Bednarski, Carolyn R. Bertozzi, Jon O. Nagy